Eupraxia Pharmaceuticals to Participate at Upcoming Conferences and Host a Virtual Analyst DayGlobeNewsWire · 2 days ago
Eupraxia Pharmaceuticals Reaches its Enrollment Target for the RESOLVE Trial Investigating EP-104GI for the Treatment of Eosinophilic EsophagitisGlobeNewsWire · Oct 15, 2026
Eupraxia Pharmaceuticals to Present at Upcoming American College of Gastroenterology (ACG) and United European Gastroenterology (UEG) Medical ConferencesGlobeNewsWire · Oct 9, 2026
Eupraxia Pharmaceuticals Reports 52-Week Data from the Highest Dose Cohort of EP-104GI in its Ongoing Phase 1b/2a RESOLVE Trial for the Treatment of Eosinophilic EsophagitisGlobeNewsWire · Sep 30, 2026
Eupraxia Pharmaceuticals Completes Transfer to the Nasdaq Global Select Market and Announces Participation in Upcoming Investor ConferencesGlobeNewsWire · Sep 8, 2026
Eupraxia Pharmaceuticals Reports Symptom Response Data from its Ongoing Phase 1b/2a RESOLVE Trial, Including New Data on Odynophagia (Painful Swallowing) in Eosinophilic Esophagitis PatientsGlobeNewsWire · Aug 13, 2026Eupraxia Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on the development of products to address therapeutic areas with unmet medical need. Its proprietary Diffusphere technology optimizes drug delivery for applications with significant unmet medical need. The company's product portfolio includes EP-104IAR, which is in Phase III clinical trial for the treatment of knee osteoarthritis; EP-104GI that is in Phase II clinical trial for treating eosinophilic esophagitis; and EP-104, which is under preclinical studies for the treatment of gastrointestinal tract, such as eosinophilic esophagitis.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 11, 2026 | -$0.23 | -$0.16 | Beat |
| May 12, 2026 | -$0.22 | -$0.23 | Miss |
| Mar 12, 2026 | -$0.16 | -$0.37 | Miss |
| Nov 4, 2025 | -$0.23 | -$0.19 | Beat |
| Aug 12, 2025 | -$0.21 | -$0.26 | Miss |
| May 6, 2025 | -$0.19 | -$0.21 | Miss |